APA (7th ed.) Citation

LAH, B., H, W., AJ, S., C, C., M, B., S, M., . . . A, C. (2023). Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 77(9), 1312. https://doi.org/10.1093/cid/ciad346

Chicago Style (17th ed.) Citation

LAH, Bevers, et al. "Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 77, no. 9 (2023): 1312. https://doi.org/10.1093/cid/ciad346.

MLA (9th ed.) Citation

LAH, Bevers, et al. "Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 77, no. 9, 2023, p. 1312, https://doi.org/10.1093/cid/ciad346.